
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra is well positioned for growth due to its innovative technologies in the acute care setting and expanding global market. With the recent acquisition by Boston Scientific at a premium price of $374 per share, it is evident that Penumbra is a market leader with strong revenue growth potential and a profitable business. Risks include potential competition from larger medical technology companies and unexpected liabilities or investigations.
Bears say
Penumbra is facing strong competition within the neurovascular market from competitors with significantly greater resources, such as Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo. These companies offer similar products and have more resources to potentially compete with Penumbra in terms of pricing, innovation, and market reach, which could lead to a decline in sales and market share for Penumbra. Additionally, potential changes in reimbursement for neurovascular procedures could negatively impact Penumbra's business. Despite the company's commitment to creating innovative products and promoting diversity, they have not tied sustainability goals to executive compensation, which may indicate a lack of long-term strategic planning.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares